You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Ellipta inhaler products

With over 40 ways to construct a triple therapy in 2019, we recognise the complexity that you face in your practice. That is why we have developed a portfolio of evidence-based medicines, all delivered in the same easy-to-use device, which has been designed specifically to suit the inspiratory flow rates of your patient.

To find out how the Ellipta portfolio can help your patients, explore the products below:

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol)

Prescribing information

COPD

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA). 1

Anoro Ellipta (umeclidinium / vilanterol inhalation powder)

Prescribing information

COPD

Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 2

Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)

Prescribing information

Asthma

Relvar Ellipta (92 micrograms/22 micrograms inhalation powder and 184 micrograms/22 micrograms inhalation powder) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists; patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist. 3 4

Incruse Ellipta (umeclidinium bromide inhalation powder)

Prescribing information

COPD

Incruse Ellipta is indicated for the ‘maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Other products in our Respiratory portfolio

   View More   

References

  1. Van der Palen, J., et al., NPJ Primary Care Respiratory Medicine, 2016. 26: p. 16079.
  2. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  3. Svedsater, H., et al., npj Primary Care Respiratory Medicine, 2014. 24
  4. Svedsater, H., et al., BMC Pulmonary Medicine, 2013. 13(72).

Anoro, Incruse, Relvar, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies